Mansukh C. Wani
Bristol-Myers Squibb
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mansukh C. Wani.
Pharmaceutical Biology | 2003
Ad Kinghorn; Norman R. Farnsworth; Djaja D. Soejarto; Geoffrey A. Cordell; Steven M. Swanson; John M. Pezzuto; Mansukh C. Wani; Monroe E. Wall; Nicholas H. Oberlies; David J. Kroll; Robert Kramer; William C. Rose; Gregory D. Vite; Craig R. Fairchild; Russell Peterson; Robert Wild
Work has continued on the investigation of plants, collected mainly from tropical rainforests, as potential sources of new cancer chemotherapeutic agents. About 400 primary samples are obtained each year, with the chloroform-soluble extract of each being screened against a battery of in vitro assays housed at the three consortial sites in our current National Cooperative Drug Discovery Group (NCDDG) research project. An HPLC-MS dereplication procedure designed to screen out “nuisance” compounds has been refined. Several hundred secondary metabolites that are active in one or more of the primary assays utilized have been obtained in the project to date, and are representative of wide chemical diversity. Some of these are also active in various in vivo assays, inclusive of the hollow fiber assay, which was installed recently as part of our collaborative research effort. A number of bioactive compounds of interest to the project are described.
Methods of Molecular Biology | 2012
Cedric Pearce; Daniel D. Lantvit; Qi Shen; David Jarjoura; Xiaoli Zhang; Nicholas H. Oberlies; David J. Kroll; Mansukh C. Wani; Jimmy Orjala; Djaja D. Soejarto; Norman R. Farnsworth; James R. Fuchs; A. Douglas Kinghorn; Steven M. Swanson
The hollow fiber assay (HFA) is a drug discovery tool to aid investigators in the prioritization of lead compounds identified by in vitro testing for further development in animal models of disease. In the HFA, cells are cultured in hollow fibers containing pores of a diameter (500 kDa) large enough for proteins and other macromolecules to enter, but too small for the cells to escape. The fibers are filled with cells, sealed and placed in the peritoneal cavity of immunodeficient mice. The mice undergo a predetermined treatment regimen after which the fibers are retrieved and the cells evaluated for activity of a target relevant to the disease modeled. The HFA combines advantages of both in vitro and in vivo assay systems. It uses the same cell lines used in culture systems, is a rapid assay, and requires fewer animals and less test substance than conventional xenograft systems. Like traditional in vivo assays, the test substance is evaluated in a live animal, which affords an initial assessment of associated toxicity and pharmacokinetic properties of the test substance.
Archive | 1994
Monroe E. Wall; Mansukh C. Wani
Archive | 2000
Monroe E. Wall; Mansukh C. Wani; Govindarajan Manikumar; Neelakantan Balasubramanian; Dolatrai M. Vyas
Archive | 2000
Monroe E. Wall; Mansukh C. Wani; Govindarajan Manikumar; Neelakantan Balasubramanian; Dolatrai M. Vyas
Archive | 2005
Mansukh C. Wani; Sharnelle S. Phifer; Dongho Lee; Eun-Kyoung Seo; Monroe E. Wall
Archive | 2002
Na-Rae Kim; Tyler N. Graf; Charles Sparacino; Mansukh C. Wani; Monroe E. Wall
Archive | 1991
Monroe E. Wall; Mansukh C. Wani; Chhagan A. Tele
Archive | 2005
Mansukh C. Wani; Sharnelle S. Phifer; Dongho Lee; Eun-Kyoung Seo; Monroe E. Wall
Archive | 2004
Mansukh C. Wani; Govindarajan Manikumar; Michael A. Wall